Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data

T. K. Owonikoko, K. P. Papadopoulos, M. Gil-Martin, V. Moreno, A. K. Salama, E. Calvo, H. Safran, A. González-Martín, R. Aljumaily, D. Mahadevan, J. Niu, K. Kal Mohan, J. Li, E. Stankevich, M. Mathias, I. Lowy, M. G. Fury, H. M. Babiker

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)viii461-viii462
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - Oct 1 2018
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Owonikoko, T. K., Papadopoulos, K. P., Gil-Martin, M., Moreno, V., Salama, A. K., Calvo, E., Safran, H., González-Martín, A., Aljumaily, R., Mahadevan, D., Niu, J., Kal Mohan, K., Li, J., Stankevich, E., Mathias, M., Lowy, I., Fury, M. G., & Babiker, H. M. (2018). Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii461-viii462. https://doi.org/10.1093/annonc/mdy289.048